Leading the digital transformation of life sciences

Medidata, a Dassault Systèmes company, is the global leader in creating end-to-end solutions to support the entire clinical trial process. Medidata built and continues to innovate the world's most used, most comprehensive clinical R&D platform for clinical development, commercial, and real-world data.

Medidata's unique cloud-based platform of innovative solutions - the Medidata Rave Clinical Cloud™ - combines a unified platform, pioneering analytics, and unrivaled industry expertise. Unifying clinical systems on a single platform reduces the cost of clinical development, time to market, and overall risk. A cloud-based platform also allows scalability, security, master data management, and ease of enhancements. By capturing and integrating such a wide array of study data, the Medidata Rave Clinical Cloud automates many of the most challenging data management workflows across randomization, supply, coding, and safety.

Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimise risk, and optimise outcomes. The company supports clinical trials in all therapeutic areas across 136 countries. This includes nearly 300 COVID-19 investigations for vaccines and therapeutics involving more than 400,000 study volunteers.

Powering smarter treatments and healthier people

Patients are at the center of the work at Medidata. Medidata's Patient Insights team involves members of the patient community in the design and testing of its solutions to help maximize engagement and minimize potential burdens. One example is the myMedidata Patient Portal, which brings us closer to remote or virtual clinical trials. This suite of products encompasses all of the capabilities of the company's patient-facing solutions for electronic consent and clinical outcomes assessment (eCOA) along with live video investigator/patient visits using myMedidata LIVE, all through one web-based intuitive interface.

Medidata is also pioneering ways to help decrease the number of patients required for certain trials where placebos might be unethical or impractical. The Medidata Synthetic Control Arm® is formed by carefully selecting patients from historical clinical trials to match the demographic and disease characteristics of the patients treated with the new investigational product. SCA's have great potential to increase the probability of success by leveraging a robust external control group to gain additional insights from early phase single arm trials and make better clinical development decisions. Shortening the time to start and complete clinical trials, and bring drugs and vaccines to market faster means millions of patients can see the benefits of medical research faster.

Stronger Together

Medidata was acquired by Dassault Systèmes in October 2019. The companies have been working together to enhance existing tools and to develop new solutions and insights necessary to confront current and future challenges in healthcare. This integration is catalyzing disruptive, positive change which will continue to differentiate Medidata, and allow the company to help more life science industry customers and more patients.

Key Facts

Medidata was founded in 1999 by Glen de Vries, Tarek Sherif, and Ed Ikeguchi.

Companies that developed 13 of the top 15 top selling drugs in 2018 used Medidata technology.

Medidata employees more than 3,000 people across 16 global sites.

Medidata has created the industry's largest structured, standardized clinical data repository with more than 6.4 million patients.

Companies that developed eight of the top 10 top selling cancer drugs in 2018 used Medidata technology.

More than 22,000 clinical trials (6,000 currently active) are on the Medidata platform.

Acorn AI, launched in April 2019, combines data, technology, and deep expertise to help life science companies deliver actionable insights across the entire continuum of clinical development.

Medidata Rave Clinical Cloud clients have realized a 64% reduction in study build time, 44% faster database lock cycle time, and 80% reduction in data correction rates.

More than one million registered users access the Medidata platform, representing more than 1,600+ customers and 18 of 20 top pharma companies.

GLOBAL HEADQUARTERS

350 Hudson Street, New York, NY10014
info@medidata.com | +1 212 918 1800

Discover more at **www.medidata.com** and follow us **Twitter @medidata, LinkedIn Medidata Solutions, Instagram Medidata Solutions**